Fatty liver disease is not one disease but at least five, according to a new Mayo Clinic analysis published on September 3, 2026 in Nature Communications. The team behind the paper says each subtype has its own biological driver, its own risk profile and, potentially, its own best treatment.
The condition itself, metabolic dysfunction-associated steatotic liver disease or MASLD, means fat is building up in the liver. It affects roughly 30 percent of adults worldwide and is a leading cause of cirrhosis, liver cancer and liver transplant. It usually has no symptoms in its early stages, which is one reason it is often missed.
The Mayo Clinic team, working with researchers at Virginia Tech, combined genetic sequencing data with routine clinical data (liver enzymes, body mass index, cholesterol, blood sugar and coexisting conditions) from more than 4,600 patients. Five biologically distinct clusters emerged from that data.
Not just a lifestyle disease
The most consequential finding may be that some subtypes are primarily driven by inherited genetic variants rather than by weight or blood sugar. That challenges the widespread assumption that fatty liver is always a lifestyle disease. Patients in the genetic subtypes showed a higher risk of progressing to advanced liver disease, and this risk was present even in people without the classic metabolic risk factors of obesity or type 2 diabetes, according to the Mayo Clinic team's account of the results.
Also read: Before you toss chocolate with a white coating, know what it actually means
That is a striking shift. It means a slim adult with normal cholesterol and no diabetes can still carry a fast-progressing form of the disease, and would not be flagged by traditional risk screening. Doctors have long recognized so-called lean MASLD, but this study places genetic drivers at the center of the picture.
Links to depression, sleep apnea and migraine
Not every subtype is about the liver in isolation. The researchers reported that specific subtypes were associated with depression, sleep apnea and migraine, suggesting the disease reaches further into the body than a purely hepatic label implies. Others matched the more familiar cardiometabolic pattern, with elevated cardiovascular risk alongside the liver damage.
Shulan Tian, a bioinformatician at Mayo Clinic and co-senior author, framed the value of stacking genetic and clinical data. "When clinical and genomic data are analyzed together at this scale, you begin to see patterns of disease progression that would otherwise remain hidden," she said in the Mayo Clinic statement.
Co-senior author Eric Klee said the approach could help clinicians pick out meaningful patient subgroups inside a disease that has long been treated as one condition. "What's emerging here is a way to systematically identify meaningful subgroups within complex disease," he said.
Also read: Your quick step may quietly reveal seven things about your personality
What this could mean for patients
The study does not yet change routine care. Doctors will not be sorting patients into five buckets tomorrow, and the paper's findings still need to be replicated in other populations.
But the direction of travel is toward matching treatment to biology rather than treating all fatty liver disease the same way.
The Mayo team says its next step is to test how each subtype responds to different therapies, including the GLP-1 receptor agonists now widely used for obesity and type 2 diabetes.
For readers, the practical takeaway is smaller and older, but reinforced by this work. Fatty liver disease is common, largely silent, and worth asking about, particularly for anyone with a family history of liver disease or the subtle clues that can point to it.
Also read: 7 warning signs of sleep apnea most people dismiss as just snoring
A blood panel and, when warranted, a liver scan can catch it years before symptoms appear. Anyone concerned about their liver should talk with their doctor about screening.
Also read: Hemoglobin levels by age and sex: what your blood test number means
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.